Navigation Links
PLUS Diagnostics Introduces Industry's First System to Eliminate Misidentification of Bone Marrow Samples
Date:6/3/2010

UNION, N.J., June 3 /PRNewswire/ -- For the first time, patients being tested for leukemia, lymphoma, and other blood and bone marrow malignancies can be certain that their test results are their own and not those of another patient. PLUS Diagnostics, a leading anatomic pathology company, announced today that it has introduced the industry's first system to eliminate misidentification and matching errors of bone marrow biopsy samples.

The median rate for specimen misidentification among U.S. health care providers including physician offices is as high as 1.31 for every 1,000 specimens, according to a 2008 study conducted by the College of American Pathologists. The national press has highlighted several incidents in the past year in which patients have received incorrect cancer diagnoses and treatment, or lack of treatment, because their samples were mismatched with someone else's samples.

"The consequences of misidentifying or mismatching a bone marrow sample are irrevocable. Undergoing a bone marrow biopsy procedure is incredibly painful.

Receiving an incorrect diagnosis because that biopsy sample was mismatched is traumatic at best and can be deadly at worst," said Dave Pauluzzi, president and COO, PLUS Diagnostics. "By introducing this new system, PLUS has taken another step toward enhancing patient safety throughout the testing process, from drawing the sample in the physician's office to delivering it to the laboratory for testing, to ensure that doctors and their patients can have the highest levels of confidence in their results."

The new system, know error™, matches DNA from a buccal swab taken during the biopsy procedure with bone marrow or blood provided to PLUS Diagnostics for testing. The system is PLUS Diagnostics' latest innovation since it partnered with Water Street Healthcare Partners, a leading private equity firm focused exclusively on healthcare. Over the past two years, the company has invested in building bi-coastal laboratories and introducing new tests that diagnose a broad scope of cancers and diseases.

"Our focus is providing physicians and specialists with innovative services that meet their unique needs," said Pauluzzi. "We are constantly searching for and investing in the newest science and technologies that will support them with achieving the best possible outcomes for their patients."

About PLUS Diagnostics

PLUS Diagnostics is a leading national anatomic pathology company that provides a full range of multi-specialty services, including extensive diagnostic procedures and specialist consultations. Accredited by the College of American Pathologists, PLUS Diagnostics has long been recognized for exceptional service and quality. The company currently focuses on a broad base of specialty pathology services, including urology, gastroenterology and hematology/oncology. For more information, visit www.plusdx.com.


'/>"/>
SOURCE PLUS Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Distinction of Quality for Dilon Diagnostics
2. Novartis Vaccines & Diagnostics to Pay More Than $72 Million to Resolve False Claims Act Allegations Concerning TOBI
3. Ambry Genetics and RainDance Technologies Announce Partnership for Diagnostics and Genomics Services Utilizing the RDT 1000 for Sequence Enrichment and Targeted Resequencing Validation
4. Home Diagnostics Selects Parago to Deliver Consumer Incentives Focused on Best Customer Experience
5. Dilon Diagnostics Receives ISO 13485 Certification
6. Quest Diagnostics Unveils Care360(TM) EHR
7. PRA International Hosts a Late Phase Services Webinar Establishing Value for Diagnostics & Biomarkers in a Real-Life Setting
8. Exagen Diagnostics Enters Into Exclusive Agreement With EndoChoice
9. AstraZeneca and Dako Sign Agreement to Develop Companion Diagnostics for Cancer Treatments
10. Sword Diagnostics Announces Availability of Proprietary Detection Technology for Ultrasensitive Immunoassays.
11. Inverness Medical Innovations Offers to Acquire Standard Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ON , Feb. 10, 2016 /PRNewswire/ - The ... , has announced the release of an anti-radiation ... is a revolutionary breakthrough in the treatment of ... radiation exposure. It will assist in the healing ... present. It will also protect only the healthy ...
(Date:2/10/2016)... KANSAS CITY, Mo. , Feb. 10, 2016 ... the pharmaceutical industry, recently identified an industry-wide trend ... a tool that allows organizations to efficiently deliver ... surveys, one in 2011 and another in 2015, ... are armed with tablet devices and DSAs, many ...
(Date:2/10/2016)... Feb. 9, 2016 CTI BioPharma Corp. ... an update regarding the clinical studies being conducted ... for pacritinib. Following the issuance of the Company,s ... clinical hold issued by the U.S. Food and ... Company received an oral communication from the FDA ...
Breaking Medicine Technology:
(Date:2/10/2016)... , ... February 10, 2016 , ... ... together to expand dental health services to the developmentally disabled in the Coachella ... Dental’s operations to a new facility at 71-949 Highway 111, Suite 100-B, in ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix announced ... Emergency Medicine , an emergency medicine professional association, to support the organization's newly ... The American Academy of Emergency Medicine, or AAEM, seeks to empower emergency physicians ...
(Date:2/10/2016)... SAN FRANCISCO, Calif. (PRWEB) , ... February 10, 2016 , ... ... category: Best Water Brand. There were three leading bottled water brand owners that topped ... edge services that enhance connectivity and optimize conversion. The premier brand was Tibet 5100, ...
(Date:2/10/2016)... Louis, Missouri (PRWEB) , ... February 10, 2016 ... ... 2016, in San Diego, will bring together more than 200 of the country’s ... healthcare for the future. , “The true benefit of the Forum is the ...
(Date:2/10/2016)... ... , ... Armune BioScience signed a definitive agreement with ARCpoint ... across the country. Launched in April of 2015, Apifiny is the only cancer specific, ... order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized ...
Breaking Medicine News(10 mins):